Hypocalcemia News and Research

RSS
Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Viewpoints: 'Blunders' on Ebola; McConnell's strange logic on Obamacare; temporary victory for Texas women

Viewpoints: 'Blunders' on Ebola; McConnell's strange logic on Obamacare; temporary victory for Texas women

Study on widespread vitamin D deficiency among patients who undergo thyroidectomy

Study on widespread vitamin D deficiency among patients who undergo thyroidectomy

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Denosumab increases bone density for postmenopausal women with osteoporosis

Denosumab increases bone density for postmenopausal women with osteoporosis

Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

NPS Pharmaceuticals reports net global product sales of $15.3 million for Q4 2013

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

FDA accepts NPS Pharmaceuticals' Natpara BLA for review

NPS Pharmaceuticals' Natpara gets orphan drug designation for treatment of hypoparathyroidism

NPS Pharmaceuticals' Natpara gets orphan drug designation for treatment of hypoparathyroidism

NPSP to conduct open-label study to evaluate teduglutide in pediatric patients with SBS

NPSP to conduct open-label study to evaluate teduglutide in pediatric patients with SBS